Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 7Leukemia, Myeloid, Acute 6Breast Neoplasms 6Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Skin Neoplasms 3Mesothelioma, Malignant 3Lymphoma, Non-Hodgkin 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Stomach Neoplasms 2Sarcoma 2Recurrence 2Rectal Neoplasms 2Pleural Effusion, Malignant 2Neuroblastoma 2Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Leukemia, Myeloid 2Leukemia 2Head and Neck Neoplasms 2Glioblastoma 2Esophageal Neoplasms 2Carcinoma, Merkel Cell 2Urinary Bladder Neoplasms 1Turcot syndrome 1

Interventions

toripalimab 2pembrolizumab 2Celecoxib 2sintilimab 1dostarlimab 1camrelizumab 1Radiation Dose Hypofractionation 1Nivolumab 1Neoadjuvant Therapy 1Ipilimumab 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Turcot syndrome × Interleukin-2 × Clear all
NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡